The Impact ofConcomitantProton Pump Inhibitors Therapy on Clinical Outcome of Cancer
Patients Treated with
Immune Checkpoint Inhibitors: A Meta-analysis
Xing Cao 1†, Yafei
Wang2 †,
Wei Huang1, Panyun Li1, Chongjie
Guo1, Yuhui Li1*
1Department of
Oncology,
The Central Hospital of Wuhan,
Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, Hubei, China
2Department of Respiratory and Critical Care Medicine,
The Central Hospital of Wuhan, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, Hubei, China
† These authors share first authorship
* Correspondence:
Yuhui Li
huihui090718@126.com
Background:In patients with advanced cancer receiving immune checkpoint inhibitors
(ICIs) therapy, there are conflict perspectives about the influence of
concomitant use of proton pump inhibitors (PPIs). We are aimed at
exploring the influence of concomitant PPIs exposure on clinical outcome
among cancer patients receiving ICIs treatment.
Methods: We searched relevant literatures in PubMed, EMBASE,
and the Cochrane Library without language restrictions. We extracted the
data from selected studies and calculated the pooled hazard ratios (HRs)
with 95% confidence intervals (CIs) through professional software for
overall survival (OS) and progression free survival (PFS) among cancer
patients undergoing ICIs therapy exposed to PPIs.
Results: Fourteen studies including 6716 advanced cancer
patients receiving ICIs treatment were appropriate for analysis judging
by pre-set inclusion and exclusion criteria. The result indicated that
concomitant PPIs exposure was significantly related to shorter OS (HR
1.388; 95%CI:1.278-1.498, P<0.001) and PFS (HR
1.285;95%CI:1.193-1.384, P<0.001) among multiple cancer
patients receiving ICIs therapy.
Conclusions: Our meta-analysis showed that concomitant PPIs
exposure had adverse impact on clinical outcome among patients receiving
ICIs therapy. Clinical oncologists must be cautious of PPIs delivery
during ICIs treatment.
Keywords:meta-analysis, immune
checkpoint inhibitors (ICIs),overall survival (OS),
proton pump inhibitors (PPIs), progression free survival (PFS).